Compare Heron Therapeutics Inc (HRTX) vs Kinross Gold Corporation (KGC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Kinross Gold Corporation — how do they compare? Heron Therapeutics Inc trades at $0.4 (market cap $68.01M), while Kinross Gold Corporation trades at $23.7 (market cap $27.62B). The key difference: Kinross Gold Corporation is far larger — about 406.1× Heron Therapeutics Inc's market cap, and Kinross Gold Corporation pays a 0.69% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Kinross Gold Corporation for 53 Days on average.
| HRTX | KGC | |
|---|---|---|
Market Cap | $68.01M | $27.62B |
Volume | 1,891,941 | 6,347,266 |
Sector | Health | Basic Materials |
52-Week High | $1.49 | $38.06 |
52-Week Low | $0.27 | $22.47 |
Typical Hold Time | 35 Days | 53 Days |
Enterprise Value | $174.75M | $25.70B |
Dividend Yield | — | 0.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.3967, up 1.72% today, with a bullish technical signal from moving averages but mixed earnings. The company reported a net loss of $20.20 million in 2025, with revenue of $154.90 million, and has a high gross margin of 70.07% but negative profitability metrics. Recent Q2 2026 results missed EPS estimates, though Q4 2025 beat expectations. Analyst consensus is strongly bullish with 17 buy ratings.
The outlook is cautious due to persistent losses and cash burn, but strong analyst support and a low P/S ratio of 0.44 may appeal to value investors. Key risks include ongoing unprofitability and competitive pressures in the biotech sector. Investors should weigh the high institutional optimism against fundamental challenges.
Kinross Gold (KGC) trades at $23.74, up 2.42% with strong fundamentals including 37.52% net margin and 36.95% ROE. The stock shows bearish technical signals despite recent earnings beats and analyst consensus of $38.80 price target. Recent news highlights production guidance cuts and increased shareholder returns, creating mixed sentiment.
KGC offers attractive valuation with 8.87 P/E but faces near-term headwinds from production issues. The company maintains strong cash flow growth and balance sheet strength, though legal investigations and operational challenges present risks. Wall Street maintains bullish long-term outlook with 59% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Kinross Gold Corporation
Kinross Gold is a Canada-based senior gold producer, producing roughly 2.4 million gold equivalent ounces in 2020. The company had 30 million ounces of proven and probable gold reserves and 59 million ounces of silver reserves at the end of 2020. It operates mines and focuses its greenfield and brownfield exploration in the Americas, West Africa, and Russia. The company has historically used acquisitions to fuel expansion into new regions and production growth.
Read more on KGC →
